化合物SBI-115 T7428

Product Introduction
Bioactivity


英文名: SBI-115

描述: SBI-115 是TGR5 (GPCR19)拮抗剂，对 TGR5 降低多囊性肝病的肝囊肿形成具有抑制作用。

细胞实验: cAMP was detected by the Bridge-It cAMP designer cAMP assay. Cholangiocytes (10,000/well) were incubated with TLCA, OA, C1 and C2 (all, 25 μM), SBI-115 (100 and 200 μM) and pasireotide (20 μM) for 15–30 min. Doses of drugs were chosen based on published data or dose ranging (SBI-115). Cell proliferation was determined by CellTiter 96 Aqueous One Solution Cell Proliferation Assay ?and by cell counting using the Cellometer Auto4 ?cell counter.?Cholangiocytes (2500 cells/well) were grown for 24–48 hours and then treated with TGR5 agonists (all, 25 μM), SBI-115 (100 and 200 μM) and pasireotide (20 μM) for additional 24 hours.?Alterations in cell proliferation after treatment were expressed as percent change compared to un-treated cholangiocytes in which cell proliferation was considered to be equal 100%.

体内活性: 通过TLCA刺激胆管细胞后接受SBI-115处理，对细胞增殖的抑制的概率为32-48%。

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 150 mg/mL (440.17 mM)


关键字: G protein-coupled Bile Acid Receptor 1 | GPCR19 | TGR5 | GPBAR1 | Inhibitor | G-protein coupled receptor 19 | SBI 115 | SBI-115 | SBI115 | inhibit

相关产品: INT-777 | BAR502 | Ursodeoxycholic acid sodium | BAR 501 impurity | INT-767 | Deoxycholic acid | L-692429 | SB756050 | Deoxycholic acid sodium salt | TC-G 1005

相关库: Anti-Cancer Compound Library | Membrane Protein-targeted Compound Library | Bioactive Compounds Library Max | Inhibitor Library | GPCR Compound Library | NO PAINS Compound Library | Bioactive Compound Library

化合物SBI-115 T7428信息由TargetMol中国为您提供，如您想了解更多关于化合物SBI-115 T7428报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途